Rajesh Ullanat

Mylan Pharmaceuticals
Head, Global Biologics Research and Development
Dr Ullanat has significant experience in key senior management positions leading multi-functional teams associated with Biopharmaceutical R&D. Dr Ullanat has significant experience related to Global Biosimilar development especially with respect to EMA and US-FDA and has led regulatory submissions for multiple Biosimilar development programs till date leading to the approval of the first biosimilar for Trastuzumab by US-FDA in 2017 and a biosimilar for Insulin Glargine by EMA in 2018.

My Speakers Sessions

Tuesday, June 26